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1. Introduction 
Inflammatory Bowel Disease (IBD) is a disorder of the gastrointestinal tract that is 
characterised by chronic inflammation, with high incidence in Westernised countries 
(Yamamoto et al., 2009). Long-chain n-3 polyunsaturated fatty acids (PUFA), in particular 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are purported to be 
important for maintaining health and protection against disease (Connor, 2000). They 
exhibit beneficial effects with respect to cardiovascular diseases, rheumatoid arthritis, 
inflammatory diseases and neurodegenerative illnesses (Wahrburg, 2004). PUFA can 
modulate the inflammatory response (Calder, 2008) and could therefore be an important 
factor in the course of IBD. Several studies have tested the anti-inflammatory potential of 
pure n-3 PUFA extracts, fish oil and whole fish, however, the results of these studies are 
inconsistent (effects of dietary n-3 PUFA on animal models of colitis reviewed in Calder, 
2008; effects of dietary n-3 PUFA in intervention studies with IBD patients reviewed in 
Ferguson et al., 2010). Nevertheless, experimental evidence (Knoch et al., 2009) has shown 
potential anti-inflammatory effects of dietary EPA supplementation, a nutrient which is 
found in high levels in salmon. Furthermore, New Zealand IBD patients recorded a higher 
tolerance to salmon compared with other foods on the basis of a food frequency 
questionnaire (Triggs et al., 2010) and salmon has shown beneficial effects for patients with 
mild IBD (Grimstad et al., 2011). Various factors play a role in the development of IBD, 
however, the focus of this review is the effect of dietary n-3 PUFA and n-3 PUFA-rich food 
such as salmon. 
2. Background 
2.1 Inflammation in inflammatory bowel disease 
The inflammatory response is the beginning of an immunological process and is necessary 
to protect the body against invading pathogens and toxins. The response is typified by 
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activation/production of at least the following four classes of active molecules (Chapkin et 
al., 2009): (i) adhesions molecules (e.g. vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1) and E-selectin) on the surface of endothelial 
cells, allowing leukocyte binding and subsequent diapedesis; (ii) inflammatory cytokines 
(e.g. tumor necrosis factor alpha (TNFǂ), interleukin (IL) 1, IL6 and IL8); (iii) arachidonic 
acid (AA)-derived eicosanoids; and (iv) inflammatory mediators (e.g. platelet activating 
factor). The activation/production of these molecules must be ordered and controlled to 
avoid excessive damage to host tissue and chronic inflammatory disorders (Calder, 2006). 
This defect in resolving inflammation and returning the target tissue back to homeostasis 
is a hallmark of IBD (Chapkin et al., 2009). While the rate of new cases of IBD is beginning 
to stabilise in high-incidence areas, including northern Europe and North America, 
countries with traditionally low occurrence rates (e.g. southern Europe, Asia and 
developing countries) are reporting an increased rate of new patients (Loftus, 2004). 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two most common forms of IBD 
and although the two forms have distinctive characteristics, they share many common 
symptoms and can be difficult to distinguish clinically (Lee & Buchman, 2009; Teitelbaum 
& Allan Walker, 2001). The aetiology of IBD is largely unknown, but it is generally 
accepted that genetic factors and the environment play a role (Ferguson, 2010; Hanauer, 
2006; Lee & Buchman, 2009). Furthermore, the tolerance of the mucosal immune system to 
the commensal intestinal microbiota is disrupted and dysregulation of the immune 
system occurs (Duchmann et al., 1995). 
Observations in twin studies have highlighted that susceptibility to IBD, in particular CD, is 
inherited (Bouma & Strober, 2003). The genetics of IBD is complex and it is suggested that 
variations in key genes, for example single-nucleotide polymorphisms (SNPs), play a role. 
SNPs are genetic variations in the DNA sequence, whereby only a single nucleotide is 
changed. Approximately seven million common SNPs have been found across the human 
population (Hinds et al., 2005). While only a few of these may have a functional effect (Stover, 
2006), some variations can affect health or even cause disease (Lee & Buchman, 2009). 
Currently, 99 susceptibility loci/genes are known to contribute susceptibly to IBD (Lees et al., 
2011). One of the first susceptibility loci was found to be a polymorphism of the caspase 
recruitment domain family member 15 (CARD15) gene, which encodes the protein nucleotide-
binding oligomerization domain 2 (NOD2) (Hugot et al., 1996; Hugot et al., 2001).  
Environmental factors such as dietary changes, smoking, oral contraceptives, appendectomy 
and stress can affect the development of IBD (Krishnan & Korzenik, 2002; Loftus, 2004). In 
the last three decades, the incidence of IBD in Japan has increased sharply, correlating with 
changes in dietary preferences towards a Western-type diet (Yamamoto et al., 2009). This 
implies that dietary choice is an important factor in the development of IBD. The lipid 
profile of Western-type diets features excessive amounts of saturated fats and n-6 PUFA, but 
a deficiency of n-3 PUFA. This imbalance leads to an altered n-6/n-3 ratio, which may 
promote the pathogenesis of many diseases including IBD (Simopoulos, 2008). Thus 
increasing the n-3 PUFA intake and lowering the ratio of n-6/n-3 PUFA in the diet may 
reduce the risk of developing chronic diseases.  
The molecular mechanisms underlying the interaction of nutrients including n-3 PUFA with 
an individual’s genome are very complex, and also poorly understood (Stover, 2006; Weaver 
et al., 2009). To improve the understanding of these gene-diet interactions, the field of 
nutrigenomics has evolved with the aim of developing a personalised strategy for health 
maintenance or disease treatment (Ferguson, 2010). In nutrigenomics research, nutrients are 
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considered signalling molecules that can target the cellular sensor system and therefore 
subsequently influence gene expression, protein expression and metabolite production 
(Subbiah, 2008). These dietary signals can cause changes in the organism, tissue or single 
cells and subsequently influence homeostasis (Müller & Kersten, 2003).  
2.2 Dietary intake of lipids 
2.2.1 Fatty acids 
Fatty acids form the major component of dietary fats, and dietary sources range from free 
fatty acids to phospholipids, sterols and triacylglycerol (TG) (Ratnayake & Galli, 2009). The 
term fatty acid describes a carboxylic acid with an aliphatic chain that can be saturated or 
unsaturated. The degree of un-saturation is addressed by the number of double bonds 
between the carbon atoms of a fatty acid. A fatty acid that contains two or more double 
bonds between the carbon atoms is classified as polyunsaturated, while monounsaturated 
fatty acids (MUFA) contain only one double bond. The classification into n-3 and n-6 PUFA 
is based on the position of the first double bond, starting from the terminal methyl end. In 
general, short-chain unsaturated fatty acids refer to 19 or fewer carbon atoms, long-chain to 
20-24 carbon atoms and very-long-chain to 25 or more. The reactivity of fatty acids increases 
with double bonds; therefore, saturated fatty acids are more stable and have a longer shelf 
life than unsaturated ones (Ratnayake & Galli, 2009). 
The dietary intake of lipids is predominately through TG, which is the vast majority of lipid 
found in vegetable oils and animal fats (Ratnayake & Galli, 2009). TG are characterised by a 
glycerol backbone connected to three molecules of fatty acids (sn-1, sn-2 and sn-3, starting 
from the top of the glycerol), whereby the three hydroxyl groups from the glycerol backbone 
form an ester bond with the carboxyl groups from fatty acids (Fahy et al., 2005). 
Nutritionally, the distribution of fatty acids over the three sn-positions changes biological 
activity and absorption pattern, whereas the composition of sn-2 is of importance due to 
facilitated absorption (Ratnayake & Galli, 2009). In Atlantic salmon, the TG in the depot fat 
comprise ~70% DHA on sn-2 position, whereas EPA is nearly randomly distributed (40% on 
sn-2) (Aursand et al., 1995). In order to be absorbed by the gastrointestinal tract lining, TG 
need to be digested, i.e. broken down into smaller components (Ratnayake & Galli, 2009). 
The small intestine is the main site for fat digestion, where the pancreatic lipase hydrolyses 
TG at sn-1 and sn-3 position, yielding final products of 2-monoacylglycerols and free fatty 
acids (Mu & Porsgaard, 2005). Free fatty acids are directly absorbed through the intestinal 
wall and 2-monoacylglycerols form micelles that further diffuse to the epithelial cells, where 
they leave the micelles and enter epithelial cells by diffusion. In the enterocytes, they are 
transported to the endoplasmic reticulum in association with a fatty acid binding protein 
(FABP) and are re-synthesised to TG. Newly synthesized TG are transported out of the 
enterocyte and enter the bloodstream via the lymph vessels in the form of chylomicrons. In 
the bloodstream, the TG of the chylomicrons are hydrolysed to free fatty acids and glycerol 
that then pass through the capillary walls to be used by cells as the major substrates for 
energy production and storage (Ratnayake & Galli, 2009). Some fatty acids (e.g. DHA, EPA 
and AA) have additional roles in modulating the structural and functional properties of cells 
(Galli & Calder, 2009). 
2.2.2 Fatty acid metabolism 
Due to its abundance in food, many human populations over-consume n-6, but 
consequently lack long-chain n-3 PUFA (Calder, 2006; Ratnayake & Galli, 2009), resulting in 
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an n-6/n-3 ratio of ~10:1 to 20-25:1, which may promote the pathogenesis of many diseases 
including inflammatory disorders (Simopoulos, 1991). Whereas humans evolved on a diet 
with a ratio of ~1:1 (Simopoulos, 2008), a ratio of 4:1 is recommended as optimal (Wall et al., 
2010), but this may vary with disease state (Simopoulos, 2008). It has been suggested that 
lowering the n-6/n-3 ratio in the diet should be achieved by increasing the amount of n-3 
PUFA rather than by simply reducing n-6 PUFA, which may reduce the risk of developing 
chronic diseases (Camuesco et al., 2005; Simopoulos, 2008). The long-chain PUFA AA, EPA 
and DHA are supplied to tissues from dietary sources, either via direct supplementation or 
via the consumption of the precursor PUFA linoleic acid (LA; n-6 pathway) and ǂ-linolenic 
acid (ALA; n-3 pathway). LA and ALA cannot be synthesised in the human body, but can be 
metabolised to longer-chain fatty acids. This conversion of LA and ALA occurs via several 
elongation and desaturation steps (Fig. 1), with competition for the same enzymes on both 
pathways (Calder & Yaqoob, 2009). LA, the parent fatty acid on the n-6 PUFA pathway, is 
metabolised to AA, whereas ALA on the n-3 PUFA pathway is metabolised to EPA and 
further to DHA. However, as the conversion of ALA to EPA is limited and further 
conversion to DHA is even lower (Burdge & Calder, 2005; Garg et al., 2006), direct DHA and 
EPA supplementation is more effective than de-novo synthesis in increasing long-chain n-3 
PUFA concentrations in the cell membrane (Hamilton et al., 2005). 
3. Putative mechanisms of action 
Long-chain PUFA are taken up by inflammatory cells and incorporated into membrane 
phospholipids (Leslie, 2004). Membrane phospholipids of inflammatory cells from humans 
consuming Western-type diets possess a relatively high amount (>20%) of n-6 PUFA, 
whereas long-chain n-3 PUFA represent less than 1% of fatty acids (Calder, 2006). The result  
 
 
Fig. 1. Metabolism of n-6 and n-3 PUFA from precursor fatty acids (Wall et al., 2010) 
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is an unbalanced n-6/n-3 ratio which can promote a pro-inflammatory phenotype. The 
dietary intake of foods rich in EPA and DHA results in membrane replacement of n-6 PUFA 
in a time and dose-dependent manner, which may contribute to anti-inflammatory effects 
(Calder, 2009). How an elevated dietary intake of n-3 PUFA exerts its beneficial effects is not 
fully understood, but the putative mechanisms of action of n-3 PUFA are illustrated in Fig. 
2. These include alterations in (i) cell membrane lipid bi-layer composition; (ii) gene 
expression; and (iii) lipid mediator metabolism (Chapkin et al., 2009). The overall 
physiological outcome depends on several factors, for example, the quantity and chemistry 
of the fat ingested, the cells present, cell-specific fatty acid metabolism (oxidative pathways, 
kinetics, and competing reactions) or the nature of the stimulus (Calder et al., 2009; Jump & 
Clarke, 1999). However, the different effects of DHA versus EPA are not well studied 
(Chapkin et al., 2009). 
Lipid rafts are complex micro-domains in the cell membrane that appear to serve as 
platforms for receptor-mediated signal transduction (Calder & Yaqoob, 2007; Chapkin et al., 
2009). When incorporated into cell membrane phospholipids, n-3 PUFA can increase 
membrane fluidity (Li et al., 2005), however, lipid rafts are far more sensitive to the 
incorporation of n-3 PUFA than non-raft domains (Rockett et al., 2011). A modulation of the 
lipid composition in rafts is associated with altered signalling pathways (Li et al., 2005; 
Schley et al., 2007; Stulnig et al., 2001).  
 
 
Fig. 2. Putative mechanism of action of PUFA. These include alterations in lipid mediator 
synthesis, gene expression, lipid composition in cell membrane and signal transduction 
(Chapkin et al., 2009) 
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Dietary n-3 PUFA can be transported into the cell via passive diffusion or active protein-
mediated transport (Bordoni et al., 2006), depending on the chain size. Longer-chain fatty 
acids are actively transported via fatty acid transport proteins (FATP) 1-6 and/or CD36  
(Bordoni et al., 2006; Heimerl et al., 2006). Inside the cell, n-3 PUFA can give rise to the 
anti-inflammatory lipid mediators resolvins and protectins (Serhan et al., 2008) and in 
turn competitively inhibit the production of mainly pro-inflammatory eicosanoids from 
AA. Furthermore, alterations in gene expression by n-3 PUFA can be mediated by 
interaction with transcription factors. For example, the activation of peroxisome 
proliferator-acitvated receptors (PPARs) can suppress nuclear factor-kappaB (NFκB) 
translocation and thereby inhibit the expression levels of pro-inflammatory cytokine 
genes (e.g. IL1 or TNFǂ) (Chapkin et al., 2009). 
3.1 The formation of lipid mediators from fatty acids  
Lipid mediators including eicosanoids, resolvins and protectins are regulators of 
inflammation and are generated from long-chain PUFA (Fig. 1) (Calder, 2009). The 
biological activity and potency of lipid mediators is dependent on the PUFA substrate. The 
n-6 PUFA AA gives rise to several eicosanoids (e.g. series-2 prostaglandins and 
thromboxanes, series-4 leukotrienes), hydroperoxy- and hydroxy-eicosatetraenoic 
derivatives and lipoxins. The majority of eicosanoids derived from AA are pro-
inflammatory; however, prostaglandin E2 and lipoxin have been shown to exert anti-
inflammatory effects (Calder, 2008). EPA is the substrate for the anti-inflammatory 
eicosanoids and resolvins (e.g. series-3 prostaglandins and thromboxanes and series-5 
leukotrienes) and hydroperoxy- and hydroxy-eicosapentaenoic derivatives. DHA gives rise 
to anti-inflammatory and pro-resolution mediators (e.g. resolvins and neuroprotectin) (Wall 
et al., 2010). The enzymes which catalyse these conversions are at least two cyclooxygenase 
(COX) and several lipoxygenase (LOX) enzymes (Calder et al., 2009), thus an elevated n-3 
PUFA intake can lead to competitive inhibition of eicosanoid production from AA. 
Consequently, the pattern of lipid mediator production can be modulated towards a 
decrease in mainly pro-inflammatory eicosanoids from n-6 PUFA and an increase in anti-
inflammatory resolvins from EPA and DHA (Calder, 2008; Calder, 2009). 
3.2 Modulation of gene expression by polyunsaturated fatty acids  
As well as altering lipid mediator synthesis, dietary fatty acids can affect gene expression 
and subsequently influence metabolism, growth and cell differentiation (Jump & Clarke, 
1999). The mechanisms for these influences may be via intermediate molecules (e.g. 
transcription factors, nuclear hormone receptors and lipid secondary messengers) that 
subsequently alter gene expression, or a direct interaction with target genes (Deckelbaum et 
al., 2006). The expression levels of genes encoding several key proteins involved in 
inflammation, lipid metabolism and energy utilisation have been identified to be modulated 
by n-3 PUFA (Deckelbaum et al., 2006).    
3.2.1 Gene expression changes underlying intestinal inflammation 
Differences in gene expression and metabolic pathways underlying intestinal inflammation 
can be characterised when inflamed colon tissue from interleukin-10 gene-deficient (Il10–/–) 
mice is compared to colon tissue from healthy control mice. The gene expression levels in 
Il10–/– mice on a control diet were mainly increased in the inflammatory and immune 
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response pathway, with pro-inflammatory genes encoding cytokines (e.g. Il1ǃ and TNFǂ) or 
chemokine receptors (e.g. Ccr5) as examples (Table 2) (Knoch et al., 2009). Decreased 
expression levels were observed for genes involved in fatty acid metabolism and xenobiotic 
metabolism (Table 1) (Knoch et al., 2009). The decreased expression levels of genes 
associated with fatty acid oxidation may have a role in disease progression (Knoch et al., 
2009) and have also been observed in colon tissue of IBD patients (Heimerl et al., 2006). 
Decreased mRNA levels of genes involved in xenobiotic metabolism were observed in Il10–/– 
mice. Detoxification and biotransformation alter xenobiotics, i.e. foreign compounds (Jakoby 
& Ziegler, 1990), and a dysfunction of these mechanisms exposes enterocytes to toxic 
luminal antigens (Langmann & Schmitz, 2006), promoting local injury (Sartor, 1995) and 
contributing to the pathophysiology of IBD (Crotty, 1994; Langmann & Schmitz, 2006). 
Expression levels of genes encoding tight junction proteins were decreased in colon tissue of 
Il10–/– mice (Knoch et al., 2009). Tight junctions are intercellular barriers that regulate the  
transport of large molecules between the intestinal epithelial cells (Balda et al., 1992) and a 
dysfunction leads to impaired intestinal integrity and increased permeability (‘leaky gut’) 
(Forster, 2008). A non-invasive method to assess intestinal permeability is the urinary 
measurement after an oral dose of sugar probes, for example sucralose, mannitol and 
lactulose (Arrieta et al., 2006; Farhadi et al., 2003). In Il10–/– mice, it was found that the ratio 
of lactulose/mannitol, a marker of small intestinal barrier permeability, was increased 
compared to control mice (Arrieta et al., 2009). The urinary excretion of sucralose, which 
indicates colonic damage, was also increased in Il10–/– mice. 
 
Gene family (genes) down-
regulated in the  
 Il10–/– mouse compared to 
WT 
Pathways 
influenced in the 
Il10–/– mouse 
compared to WT 
The effect of PUFA on gene 
expression during intestinal 
inflammation Reference 
EPA (Il10–/–) AA (Il10–/–)
ATP-binding cassette 
(Abca1, Abcb1ǂ (mdr1a), 
Abcc3) 
Xenobiotic 
metabolism 
Up Up A, C 
Cytochrome P450 
(Cyp2c40, Cyp2e1)
Xenobiotic 
metabolism
Up Up A, B, C 
Glutathione S-transferase 
(Gsta4, Gstt1, Gstm1)
Xenobiotic 
metabolism
Up Up A, B, C 
Interleukin (Il6) 
Immune and 
inflammatory 
response 
Down* Down B 
Peroxisome proliferator-
activated receptor 
(PPARǂ) 
Immune and 
inflammatory 
response 
Up  A, C 
Table 1. Selected genes and their associated pathways that are down-regulated in the Il10–/– 
mouse model, compared to wild-type (WT) mice, and the effects of polyunsaturated fatty acids 
in mouse models of intestinal inflammation (Table constructed with information from (A) Knoch 
et al., 2009; (B) Knoch et al., 2010a; (C) Reiff et al., 2009). (*) indicates a non-significant change. 
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Gene family (genes) up- 
regulated in the Il10–/– 
mouse compared to WT
Pathways 
influenced in the 
Il10–/– mouse 
compared to WT
The effect of PUFA on gene 
expression during intestinal 
inflammation 
Reference 
EPA 
(Il10–/–) 
AA 
(Il10–/–) 
DHA 
(BALB/c + 
DSS) 
S100 calcium binding 
protein  (S100a8, 
S100a9) 
Oxidative stress 
response 
Up* Down Down A, B 
Tumor necrosis factor 
alpha (TNFǂ) 
Immune and 
inflammatory 
response 
Down* Down  B, C, D, E 
Tumor necrosis factor 
receptor superfamily, 
member 1b (Tnfrsf1ǃ) 
Immune and 
inflammatory 
response 
Down Down* Down A, B, D, E 
Prostaglandin-
endoperoxide synthase 
2 (COX-2) (PTGS2) 
Immune and 
inflammatory 
response 
Down* Down  C 
Chemokine (C-C motif) 
receptor (Ccr5, Ccr7) 
Immune and 
inflammatory 
response 
Down   B 
Interleukin (Il1ǃ) 
Immune and 
inflammatory 
response 
 Down Down A, B, C 
Matrix metallopeptidase 
(Mmp3, Mmp9, 
Mmp13) 
Leukocyte 
extravasation 
signalling 
 Down Down A, B, C 
Table 2. Selected genes and their associated pathways that are up-regulated in the Il10–/– 
mouse model, compared to wild-type (WT) mice, and the effects of polyunsaturated fatty 
acids in mouse models of intestinal inflammation (Table constructed with information from 
(A) Cho et al., 2011; (B) Knoch et al., 2009; (C) Knoch et al., 2010a; (D) Knoch et al., 2010b; (E) 
Reiff et al., 2009). (*) indicates a non-significant change. 
3.2.2 Modulation of gene expression by polyunsaturated fatty acids  
PUFA-enriched diets were partly able to reduce expression levels of genes associated with 
inflammation (Table 1 and Table 2) (Cho et al., 2011; Deckelbaum et al., 2006; Knoch et al., 
2009; Knoch et al., 2010a; Knoch et al., 2010b; Reiff et al., 2009). As illustrated in Table 1, 
expression levels of the PPARǂ gene were increased by EPA-enriched diets. This is 
supported by a study in a pig model of IBD, where dietary LA increased colonic PPARǄ 
gene expression levels and dietary n-3 PUFA activated PPARǅ (Bassaganya-Riera & 
Hontecillas, 2006). In this study (Bassaganya-Riera & Hontecillas, 2006), the onset of 
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experimental IBD was either delayed (PPARǄ activation) or colonic regeneration and clinical 
remission accelerated (PPARǅ activation). The expression levels of the gene encoding for the 
S100a8 protein, associated with neutrophil activation (Ryckman et al., 2003), was increased 
in UC patients compared to healthy subjects (Dieckgraefe et al., 2000). Its expression level 
was also increased in mice with experimental colitis compared to healthy mice; DHA- and 
AA-enriched diets were able to reduce increased S100a8 gene expression levels in Il10–/– 
mice, however, EPA-enriched diets were not (Cho et al., 2011; Knoch et al., 2009).  
The transcription factors NFκB and PPARs are reported to be modulated in inflammatory 
states and by dietary PUFA (Calder, 2008; Chapkin et al., 2009; Wall et al., 2010). NFκB is a 
regulator of the inflammatory response and oxidative stress (Hassan et al., 2010) and its 
activation is triggered by extracellular inflammatory stimuli, followed by translocation of 
NFκB to the nucleus and an increase in expression levels of genes associated with 
inflammation (e.g. the cytokines IL1, IL6 or TNFǂ) (Calder, 2008). Fatty acids and 
eicosanoids are natural ligands of PPARs. When activated by ligand binding, PPARs 
dimerise with the retinoid X receptor (RXR) and the dimer subsequently binds to specific 
response elements (PPREs) within promoter regions of target genes, thus modulating 
transcription of the genes (Berger & Moller, 2002). The three isotypes PPARǂ, PPARǃ/Ǆ and 
PPARǅ are encoded by different genes and exhibit broad, isotype-specific tissue expression 
patterns (Michalik et al., 2006). PPARǄ activity can be inhibited by TNFǂ which 
consequently is associated with the pathogenesis of inflammation (Ye, 2008). PPARǂ was 
shown to be an important transcriptional regulator in the small intestine (Buenger et al., 
2007) and reduced NFκB gene expression levels (Knoch et al., 2009). DHA and EPA are 
natural ligands of PPARǂ and its activation can trigger fatty acid oxidation, thus a 
deficiency in PPARǂ resulted in a dysfunction of hepatic fatty acid uptake and oxidation in 
an animal model (Lee & Kim, 2010).     
3.3 Modulation of protein expression by polyunsaturated fatty acids  
The analysis of gene expression explains only a part of the observed phenotype, as the 
increase or decrease of expression levels of a gene that code for a certain protein does not 
necessarily result in changed protein abundance (Ideker et al., 2001). Several influences, 
including the degradation of mRNA, post-translational modifications and the rate of 
degradation of the protein, can affect protein abundance. While there is published 
research on the effects of fatty acids on gene expression, there is less data available on its 
effects on protein expression. Proteomic analysis for IBD patients exists (Shkoda et al., 
2007; Zhao et al., 2011) and has identified distinctive patterns in protein expression 
compared to healthy subjects. The studies showed that the biological processes 
inflammatory response and oxidative stress, signal transduction, energy generation 
including lipid metabolism and cell apoptosis were influenced (Shkoda et al., 2007; Zhao 
et al., 2011). How n-3 PUFA can influence protein expression in Il10–/– mice should 
therefore provide further insights into the putative molecular mechanisms behind the 
observed phenotypical changes between Il10–/– and control mice. 
4. The role of foods in IBD 
Minor components in foods such as antioxidants or PUFA are necessary for several 
processes in the human body (Visioli et al., 2003). The use of pure extracts of these 
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components has occasionally been promoted and the effects of these single nutrients have 
been reviewed. For example, curcumin (a polyphenolic compound found in some foods 
such as the spice turmeric), reduced histological signs of colonic inflammation and the 
expression levels of genes in pro-inflammatory pathways in a mouse model of IBD (Nones 
et al., 2009). The influences of dietary PUFA supplementation on mice with chronic colitis 
were studied by Knoch et al. (2009; 2010a) and Roy et al. (2007). The results of these 
experiments showed mild anti-inflammatory effects for both n-3 and n-6 PUFA, the former 
via the activation of a PPARǂ transcription factor. However, single nutrients may exert 
different protective effects than whole foods which provide these components. Possible anti-
inflammatory features of extracted long-chain n-3 PUFA (Calder, 2009; Knoch et al., 2009; 
Knoch et al., 2010a; Roy et al., 2007) may function differently when in a food matrix (Kris-
Etherton & Hill, 2008). Dietary n-3 PUFA can be ingested as highly purified extracts of 
single n-3 PUFA, fish oil (mixture of PUFA) or marine fish (nutrient package and rich in n-3 
PUFA). One of the advantages in the consumption of whole fish is nutritional diversity, 
which favours possible synergistic effects (He, 2009; Rudkowska et al., 2010). 
4.1 The benefits of dietary fish intake 
Compared to other foods, marine fish (especially salmon and tuna) are naturally rich in 
long-chain n-3 PUFA (Mozaffarian, 2006). Early evidence of potential health benefits of fish 
was found in the dietary habits of Greenland Eskimos (Bang et al., 1976). The food 
consumed by Eskimos is mostly of marine origin and provides high amounts of long-chain 
n-3 PUFA including EPA and DHA. An important correlation between dietary fish intake 
and a lower risk of coronary atherosclerotic diseases was found (Bang et al., 1976).  
Long-chain n-3 PUFA accumulates in fish through the food chain (Sargent, 1997). The basis 
of the food chain is marine phytoplankton, which synthesises long-chain n-3 PUFA by 
conversion of LA to ALA (Hamilton et al., 2005). The uptake of phytoplankton by marine 
zooplankton leads to the accumulation of n-3 PUFA in the phospholipids of cellular 
membranes and through the ingestion of zooplankton, n-3 PUFA accumulates in fish. In 
general, deep water fish including salmon, herring, mackerel or tuna are classified as oily 
fish, with the main fat storage being the flesh. The lipid reserves of lean fish, for example 
cod, haddock or whiting, are in the liver. Cod liver is therefore a rich source of n-3 PUFA, as 
well as the fillets of salmon, herring etc. (Sargent, 1997). The n-3 PUFA content in fish varies 
with species, age, size, reproduction stage, season, geographical location and diet (Larsen et 
al., 2010).  
The advantage of whole fish consumption compared to supplements is nutritional diversity. 
A common problem in IBD is malnutrition, caused by for example poor dietary intake or 
impaired nutrient absorption (O'Sullivan & O'Morain, 2006). Fish could compensate for the 
micronutrient deficiencies and provide a mechanism to elevate the levels of several minerals 
and vitamins. Of particular clinical relevance are deficiencies in calcium, vitamin D and B12, 
folate (Goh & O'Morain, 2003), zinc (Hendricks & Walker, 1988) and vitamin B6 (Saibeni et 
al., 2003), which are all contained in fish (Sidhu, 2003). Several of these micronutrients were 
able to suppress inflammation in rodents with experimental colitis. For example, vitamin E 
protected the rat colon from oxidative stress, which is associated with inflammation 
(González et al., 2001). Oxidised PUFA can activate transcription factors such as NFκB and 
subsequently trigger pro-inflammatory gene expression, whereby vitamin E as an 
antioxidant compound in salmon might prevent oxidation and in turn NFκB activation 
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(Calder et al., 2009). The supplementation of vitamin D and calcium showed protective 
effects in Il10–/– mice (associated with TNFǂ pathway) (Zhu et al., 2005) and selenium 
protected rats with experimental colitis (Tirosh et al., 2007). Furthermore, fish is also an 
excellent source of amino acids, such as taurine, arginine and glutamine, which may 
contribute to anti-inflammatory effects (He, 2009; Rudkowska et al., 2010).  
A positive association of salmon with IBD has been identified among New Zealand CD 
patients (Triggs et al., 2010). 446 patients rated food items and their effects on disease 
symptoms. No single food item was considered beneficial in all cases, however a small 
number of foods were frequently perceived to be beneficial, including white fish, salmon 
and tuna. These results indicated that salmon was perceived to be one of the most beneficial 
foods for those patients. Furthermore, intervention studies involving patients with active 
CD showed a favourable influence of salmon on IBD. After 8 weeks of a dietary intake of 
600 g Atlantic salmon per week, the clinical colitis activity index was improved and the n-
3/n-6 ratio increased (Grimstad et al., 2011). Another study (Pot et al., 2010) revealed that 
after 6 months, patients with previous colorectal adenomas or non-active UC showed 
partially decreased inflammation markers. The patients consumed either fatty (farmed 
salmon) or lean fish (Icelandic cod) in 2 x 150 g portions per week. Interestingly, the 
consumption of cod (lean fish) showed the same results as the salmon group, suggesting 
that not only oily fish, but also lean fish can exert anti-inflammatory effects (Pot et al., 2010). 
4.2 Whole foods vs. supplements 
Bioavailability is defined as “the proportion of a drug or other substance which enters the 
circulation when introduced into the body and so is able to have an active effect”(Oxford 
Dictionaries, 2010). Dietary n-3 PUFA can be provided by fatty fish, fish oil capsules or via  
foods enriched with n-3 PUFA (e.g. milk and meat)  (Kitessa et al., 2001; Knowles et al., 2004; 
Ponnampalam et al., 2002), however its bioavailability may differ between these formats. 
Fish intake may increase the bioavailability of n-3 PUFA because: (i) the ingestion of whole 
foods is followed by a more effective activation of digestion/absorption in the intestine 
compared to capsules (Elvevoll et al., 2006; Galli & Calder, 2009; Visioli et al., 2003); (ii) 
lipids in fish are mostly in form of TG, with n-3 PUFA mostly in position sn-2, which 
facilitates absorption (Aursand et al., 1995; Ratnayake & Galli, 2009); and (iii) the 
bioavailability of EPA is improved when co-ingested with a high-fat meal (Lawson & 
Hughes, 1988a). Human studies have found that the n-3 PUFA within salmon are more 
efficient at increasing n-3 PUFA levels in serum and plasma compared to fish oil capsules 
(Elvevoll et al., 2006; Visioli et al., 2003). However, this contrasts to results from Arterburn et 
al. (2008), who found that algal-oil capsules and cooked salmon are nutritionally equivalent 
sources of DHA, thus representing an alternative to fish. The results of these studies 
(Arterburn et al., 2008; Elvevoll et al., 2006; Visioli et al., 2003) may depend on several 
factors, for example genetic differences in the individual subjects, but also on the oxidation 
rate of n-3 PUFA in capsules or differences in encapsulation (e.g. hard vs. soft gelatine 
capsules) (Ferguson et al., 2010).   
5. Limitations 
Dietary recommendations of two servings of fish per week require unlimited sources of fish. 
However, wild-caught fish are finite and some species are already classified as over-fished 
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(Naylor et al., 2000). Producing farmed fish in aquacultures may not be sustainable long-
term. Apart from water pollution or habitat destruction, aquacultures require large inputs of 
wild fish for feed (Jenkins et al., 2009; Naylor et al., 2000). For example, the production of 
one kilogram of farmed fish, raised on feeds fortified with fish meal and oil, requires 
approximately three kilograms of wild fish (Naylor et al., 2000). To lower fish input in feed, 
n-3 PUFA-rich fish oil was replaced by n-3 PUFA-deficient vegetable oil. However, this 
resulted in lower levels of n-3 PUFA in salmon flesh, which would therefore not serve the 
purpose of increasing DHA and EPA in the human diet. 
For those who do not wish to consume fish, enrichment of foods which are not naturally 
rich in long-chain n-3 PUFA is an option (Bermingham et al., 2008; Calder & Yaqoob, 
2009; Whelan et al., 2009). These include n-3 PUFA-enriched eggs, meat (Knowles et al., 
2004; Ponnampalam et al., 2002) or milk (Kitessa et al., 2001) that can be produced by 
bio-fortification (feeding the animal n-3 PUFA-rich feeds) or post-harvest modification of 
foods (n-3 PUFA-rich oils into foods) (Bermingham et al., 2008; Whelan et al., 2009). 
However in most cases, fish oils are used for elevating the n-3 PUFA levels. In order to 
reduce pressure on wild fish stocks, it is important to find an alternative source of n-3 
PUFA. A possible solution could be DHA-rich algal oil, which is considered as plant-
derived, thus also appropriate for vegetarians for direct supplementation (Whelan & 
Rust, 2006). 
Evidence for the protective effects of n-3 PUFA is inconsistent, possibly due to various 
factors (Ferguson et al., 2010). In vitro models can not mimic the complexity of an entire 
organism, which makes the use of animal models necessary. However, disease pathogenesis 
differs across animal models, thus making it difficult to compare results (Hegazi et al., 2003; 
Hegazi et al., 2006). Diets enriched with n-3 PUFA which are fed to animals differ in their 
sources and range from highly purified extracts of single PUFA (i.e. DHA or EPA) to fish oil 
and marine fish. Although these sources generally represent an excess of n-3 PUFA, 
bioavailability might change with the form provided (e.g. free fatty acids, ethyl esters, TG or 
embedded in a food matrix) (Lawson & Hughes, 1988b). Additionally, the time point of 
supplying the PUFA diets may be an important factor for the outcome of the study 
(Ramakers et al., 2008). As a preventive approach, the feeding of diets prior to colitis 
induction could exert different effects when compared with a therapeutic approach, in 
which the diets are fed when colitis is already present (Ramakers et al., 2008). An 
important factor is the dose of the supplemented n-3 PUFA. Trebble et al. (2003) 
demonstrated that the production of the pro-inflammatory cytokines TNFǂ and IL6 by 
cells appear to follow a ‘U-shaped’ dose response when n-3 PUFA supplementation was 
present. In this study, the supplementation of dietary fish oil in healthy humans resulted 
in a significantly decreased TNFǂ and IL6 production of the peripheral blood 
mononuclear cells at the lowest level (0.3 g n-3 PUFA per day). A maximum inhibition 
was observed at intermediate levels (1.0 g n-3 PUFA per day), but the least inhibition at 
highest supplementation levels (2.0 g n-3 PUFA per day). Thus, the dose of the dietary n-3 
PUFA may considerably influence the outcome of n-3 PUFA supplementation studies 
(Trebble et al., 2003). A possible explanation for the observations might be found in the 
molecular mechanisms by which n-3 PUFA influences cell function, i.e. altered eicosanoid 
synthesis, signal transduction or gene expression. It is hypothesised that those 
mechanisms have maximum effects at different intake levels of n-3 PUFA and thus a ‘U-
shaped’ dose–response curve results (Trebble et al., 2003).  
www.intechopen.com
 
The Effects of n-3 Polyunsaturated Fatty Acid-Rich Salmon on Inflammatory Bowel Diseases 
 
233 
6. Conclusion 
Fish is high in protein, low in saturated fat and it provides high amounts of n-3 PUFA (He, 
2009). Therefore, as part of a healthy lifestyle, fish should be consumed at least twice per 
week, and one of these servings should be oily fish (Kris-Etherton & Hill, 2008; Scientific 
Advisory Committee on Nutrition/Committee on Toxicity, 2004). The underlying molecular 
mechanisms by which salmon-containing diets influence intestinal inflammation are not 
well known. In Il10–/– mice, pure EPA can reduce colon inflammation and regulate gene and 
protein expression involved in various pathways (Knoch et al., 2009), leaving a unique 
dietary signature. A genome-wide approach can be applied with the use of ‘omics’-
technologies – transcriptomics (gene expression analysis) and proteomics (protein 
expression analysis) – to identify metabolic pathways and key gene/protein regulatory 
‘hubs’ which are responsive to n-3 PUFA-enriched diets, and through which anti-
inflammatory effects are exerted. A metabolomic approach can be used to identify 
metabolites in mouse urine and plasma samples that are influenced by the n-3 PUFA-
enriched diets. These metabolites could serve as biomarkers for future human clinical 
intervention studies to assess the effect of these diets non-invasively. Future studies need to 
determine if the dietary intake of salmon is more beneficial than fish oil (mixture of n-3 
PUFA) or single n-3 PUFA (i.e. DHA or EPA). Further, if the intake of fish has anti-
inflammatory effects, can these be attributed to DHA or EPA, a combination, or synergistic 
effects with other nutrients?  
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